Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.
about
New developments in aminoglycoside therapy and ototoxicityCharacteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadTherapeutic suppression of premature termination codons: mechanisms and clinical considerations (review)Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection.Evaluation of the Interaction between the Poincianella pyramidalis (Tul.) LP Queiroz Extract and Antimicrobials Using Biological and Analytical ModelsDrug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies.Outcomes in patients with gram-negative sepsis treated with gentamicinAntibiotics and bacterial resistance in the 21st century.Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance.Electrostatic interactions in aminoglycoside-RNA complexes.Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.Thionin-like peptide from Capsicum annuum fruits: mechanism of action and synergism with fluconazole against Candida species.Identification of an Inhibitor of the Aminoglycoside 6'-N-Acetyltransferase type Ib [AAC(6')-Ib] by Glide Molecular DockingAn Evaluation of the Protective Effects of Thymoquinone on Amikacin-Induced Ototoxicity in Rats.d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen.Rise and dissemination of aminoglycoside resistance: the aac(6')-Ib paradigm.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Vancomycin therapeutics and monitoring: a contemporary approach.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.A Novel Motif for S-Adenosyl-l-methionine Binding by the Ribosomal RNA Methyltransferase TlyA from Mycobacterium tuberculosis.Modeling intraocular bacterial infections.Aminoglycosides: An Overview.Antibiotic use for pneumonia among children under-five at a pediatric hospital in Dhaka city, Bangladesh.The Poisoned Well: Enhancing the Predictive Value of Antimicrobial Susceptibility Testing in the Era of Multidrug Resistance.A comparison between the nephrotoxic profile of gentamicin and gentamicin nanoparticles in mice.Finding ways to solve or prevent aminoglycoside-induced ototoxicity?Drug detoxification dynamics explain the postantibiotic effect.Towards the Prevention of Aminoglycoside-Related Hearing Loss.Application of Materials as Medical Devices with Localized Drug Delivery Capabilities for Enhanced Wound Repair.Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.Structure-Based Design and Synthesis of Apramycin-Paromomycin Analogues: Importance of the Configuration at the 6'-Position and Differences between the 6'-Amino and Hydroxy Series.Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients.Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy.The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance.Analysis of parameters in critically ill patients influencing amikacin peak levels.
P2860
Q24599985-74C36CB5-B82E-4ABB-B96C-DF30F7A6621BQ26752680-2254E08E-BC4B-4C3C-A11E-EA4FF4967803Q26822988-CEBE461A-0A5F-44BE-8DC5-C4B7CFB65016Q26853614-7563C5D1-C133-43FF-B705-BC74C941E561Q28393038-E2D8C4BB-EB77-47C5-81D6-749B3D0C60DEQ28552193-2754D6FF-DE9A-443C-A53D-CC8B35433812Q30240026-0F008BFA-D479-4D93-8865-3CFC4415CAD4Q33949330-19945638-7DDC-4FD5-9911-0543DB7D5F2CQ34156349-2ADA9E75-2736-4B50-8CD6-18FF74D9CDCCQ34982853-DB9333B8-4B8D-4883-A064-8D297A3B0BECQ35023720-8FBF0234-886B-4A59-990A-6FD052C63709Q35050629-2CDB3E7C-EB10-43AE-98B1-F112A588C118Q35867436-3FB85DF6-C77A-4D9D-A6A6-DB1862453EF7Q35906637-3AF15BDD-1012-4A9F-9FF3-9D5928248AB1Q35955677-A89DDAFE-6C2E-4EC6-8D16-4D6CBDAFB07EQ36323000-B432B09A-D94C-4B83-B8B9-8875C51F5AFAQ36446781-B1AD6034-94B7-4D9A-8725-8326EA4B9A55Q36505481-1AAED898-DFB6-4D62-B268-ABC7A2691629Q36850490-EC6A43FC-123C-4B9C-A66C-13E64F77D102Q37358664-437CA7F1-8DF7-4CC8-84C8-8D3DF72BE63FQ38062923-3847BCF2-3782-442B-BD23-5DC87BC51726Q38369608-6B81B570-C9FB-452D-A70D-718C567EEA41Q38777075-F96D031A-5BF4-42A5-8AF1-A22686B6080BQ38827899-AD3CA4D3-5028-44B7-8F81-2D819D0429DCQ38851189-CF0C97E8-150F-4511-9188-EB8CC35813C7Q40083685-0D2BC08E-FAD6-4C6D-85F8-0152282C9956Q40227755-31414170-97E3-4BD3-8A7E-E711A99679A8Q41712040-5DDF0A27-8CDC-4D94-823E-B72CE483291FQ42330819-9EC47917-66E9-436F-B76D-A5E5E7BB4175Q44932110-6E021510-0588-4C29-8702-40C7D8561E0AQ46270520-295EE2FE-9555-4BC8-B85E-A9A9C2DAB751Q47356562-E19CAAC2-FE7F-4A1A-9C4D-A48526C8EA85Q47602664-AFA82DBD-6037-472F-A28E-148C055848F1Q48093664-6205DB5A-9288-460E-9381-39BE07753FA0Q49598865-843CEC0E-6F66-4026-832A-80CAEA591CDBQ49894608-72426267-0903-44C5-BA34-82A123AE2F6DQ50977991-D12F5DDE-10C4-48FE-8316-C487C0DACDCCQ51092520-ED785394-512D-4922-AFFD-227C56063CDCQ51163450-A197B738-0682-4F6E-BF53-454C9B2CB527Q55209438-04CF56EC-44E6-4DA7-9630-E6510ADBF0D0
P2860
Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current use of aminoglycosides ...... s and monitoring for toxicity.
@en
Current use of aminoglycosides ...... s and monitoring for toxicity.
@nl
type
label
Current use of aminoglycosides ...... s and monitoring for toxicity.
@en
Current use of aminoglycosides ...... s and monitoring for toxicity.
@nl
prefLabel
Current use of aminoglycosides ...... s and monitoring for toxicity.
@en
Current use of aminoglycosides ...... s and monitoring for toxicity.
@nl
P2093
P2860
P1476
Current use of aminoglycosides ...... s and monitoring for toxicity.
@en
P2093
B A Rogers
D L Paterson
P2860
P304
P356
10.1111/J.1445-5994.2011.02452.X
P577
2011-06-01T00:00:00Z